Literature DB >> 21252937

Refining the benefit-risk framework for the assessment of medicines: valuing and weighting benefit and risk parameters.

S Walker1, L Liberti, N McAuslane, B S Levitan.   

Abstract

A common framework is necessary for the transparent articulation of the benefits and risks of a therapeutic product across disparate stakeholders. The assignment of value and weighting to each component parameter presents challenges deriving from different stakeholder objectives, methods, and perspectives. Building on prior experiences with a validated framework approach, this forum focused on identifying challenges and approaches to the assignment of values and weightings using a case study applied to a hypothetical medicinal product.

Mesh:

Year:  2011        PMID: 21252937     DOI: 10.1038/clpt.2010.290

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  Can Standardisation of the Public Assessment Report Improve Benefit-Risk Communication?

Authors:  Andrea Keyter; Sam Salek; Shabir Banoo; Stuart Walker
Journal:  Front Pharmacol       Date:  2020-06-17       Impact factor: 5.810

2.  Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Authors:  Bennett Levitan; Zhong Yuan; Alexander G G Turpie; Richard J Friedman; Martin Homering; Jesse A Berlin; Scott D Berkowitz; Rachel B Weinstein; Peter M DiBattiste
Journal:  Vasc Health Risk Manag       Date:  2014-03-26

3.  Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC).

Authors:  Hugo Arlegui; Kaatje Bollaerts; Vincent Bauchau; Gaëlle Nachbaur; Bernard Bégaud; Nicolas Praet
Journal:  Drug Saf       Date:  2020-11       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.